Constantin Volovăț

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung et al. · The Lancet Oncology · 2013 · 830 citations · Full text

Gastrointestinal Oncology, Advanced Gastric Cancer, Open-label Phase 3 +9

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Journal of Clinical Oncology · 2008 · 241 citations

Kras Mutations, Surgical Oncology, Gastrointestinal Oncology +15

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

Peter Ruf, Michael Kluge, Michael Jäger et al. · British Journal of Clinical Pharmacology · 2010 · 88 citations · Full text

<i>KRAS</i>,<i>NRAS</i>and<i>BRAF</i>mutations in Greek and Romanian patients with colorectal cancer: a cohort study

Șerban Negru, Eirini Papadopoulou, Angela Apessos et al. · BMJ Open · 2014 · 43 citations · Full text

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

Pieter W. Kamphuisen, A.Y.Y. Lee, Guy Meyer et al. · Journal of Thrombosis and Haemostasis · 2018 · 37 citations · Full text

Thrombosis, Pulmonary Embolism, Venous Thrombosis +13